Developing the Next Generation of

Sustained-release Treatments for Vision-threatening Diseases

Our mission is to reduce the burden of treatment for patients with ocular diseases through the development of proprietary, injectable products enabling less frequent administration. Our lead product, GB-102, has the potential for twice per year injections to treat patients with neovascular (wet) AMD. We are also developing new compounds to treat glaucoma and provide neuroprotection when injected twice per year into the subconjunctiva.